XASE
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others. Its LNC platform enables safe, intracellular, oral- delivery of small molecules and small oligonucleotides.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | Q1 2026 | — | -0.30 | — | $0 | — | -0.30% | -12.07% | — |
| 2026-03-31 | Q4 2025 | — | -0.26 | — | $0 | — | +0.00% | +0.50% | +30.08% |
| 2025-11-10 | Q3 2025 |
| — |
| -0.40 |
| — |
| $0 |
| — |
| — |
| — |
| — |
| 2025-08-14 | Q2 2025 | — | -1.03 | — | $0 | — | -0.19% | +5.45% | +10.91% |
| 2025-04-15 | Q4 2024 | -0.78 | -1.68 | -115.38% | $0 | ❌ Miss | -2.59% | +3.43% | +32.76% |
| 2024-11-13 | Q3 2024 | -1.00 | -0.85 | +15.00% | $0 | ✅ Beat | -10.65% | -23.94% | -20.00% |
| 2024-08-14 | Q2 2024 | -1.00 | -1.00 | +0.00% | $0 | ➖ Inline | -2.55% | -31.08% | -51.08% |
| 2024-03-27 | Q4 2023 | 0.00 | -1.50 | -100.00% | $0 | ❌ Miss | — | — | — |
Showing last 8 quarters.